Photo: Tassii/Getty Images
The White House announced it has signed nine new agreements with pharmaceutical companies Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi to offer medications through TrumpRx at discounted rates.
According to the White House, Boehringer Ingelheim's Jentadeuto for type 2 diabetes will be listed for $55 for U.S. patients, Bristol Myers Squibb's Reyataz for HIV will be $217, Genentech's Xofluza flu medication will be $50, and Amgen's Repatha, used to lower high cholesterol, will be offered through TrumpRx for $239.
TrumpRx will also offer Gilead Sciences' Epclusa hepatitis C medication for $2,425, Merck's Januvia for diabetes at $100 and Novartis' Mayzent for multiple sclerosis for $1,137, and Sanofi will reduce the price of its prescription blood thinner, Plavix, to $16.
Sanofi will also list its insulin products on TrumpRx at $35 per month’s supply, and GSK will reduce the prices of its inhaler portfolio, including its asthma inhaler Advair Diskus 500/50, to $89.
The pharma giants are also collectively investing at least $150 billion in U.S. manufacturing and donating active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve, which aims to increase the U.S. supply of such products in the event of an emergency and reduce America's reliance on foreign nations.
THE LARGER TREND
Earlier this month, Boehringer Ingelheim announced it had signed an agreement with the Trump administration that allows the pharma giant to be excluded from potential Section 232 tariffs.
The pharma giant plans to spend $10 billion to expand its research and development and manufacturing operations in the U.S. through 2028, including $1 billion for capital expenditures.
The agreement means the bulk of Boehringer's medications for U.S. patients will be produced in the United States.
In November, the White House announced it signed agreements with Eli Lilly and Company and Novo Nordisk to offer GLP-1s Zepbound, orforglipron, Ozempic and Wegovy through TrumpRx at a discounted rate.
TrumpRx launched in September and announced it brokered a deal with Pfizer to offer some of the pharma giant's medications at a discount through the prescription digital marketplace.
That deal also allowed Pfizer to avoid U.S. tariffs on overseas-made drugs for three years by offering its medications through TrumpRx.
